Results 1 to 10 of about 18,801,342 (289)

The Role of TIM-3 in Glioblastoma Progression [PDF]

Cells
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression.
Farah Ahmady, Amit Sharma, Adrian A. Achuthan, George Kannourakis, Rodney B. Luwor   +4 more
doaj   +4 more sources

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice [PDF]

The Journal of Clinical Investigation
Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin and mucin-containing molecule 3 (TIM-3) for improving graft-versus-leukemia (GVL ...
Nana Talvard-Balland, Lukas M. Braun, Karen O. Dixon, Melissa Zwick, Helena Engel, Alina Hartmann, Sandra Duquesne, Livius Penter, Geoffroy Andrieux, Lukas Rindlisbacher, Andrea Acerbis, Jule Ehmann, Christoph Köllerer, Michela Ansuinelli, Andres Rettig, Kevin Moschallski, Petya Apostolova, Tilman Brummer, Anna L. Illert, Markus A. Schramm, Yurong Cheng, Anna Köttgen, Justus Duyster, Hans D. Menssen, Jerome Ritz, Bruce R. Blazar, Melanie Boerries, Annette Schmitt-Gräff, Nurefsan Sariipek, Peter Van Galen, Joerg M. Buescher, Nina Cabezas-Wallscheid, Heike L. Pahl, Erika L. Pearce, Robert J. Soiffer, Catherine J. Wu, Luca Vago, Burkhard Becher, Natalie Köhler, Tobias Wertheimer, Vijay K. Kuchroo, Robert Zeiser   +41 more
doaj   +7 more sources

Tim-3 [PDF]

médecine/sciences, 2018
Les lymphocytes T (LT) exprimant de multiples molécules de co-stimulation inhibitrices (PD-1, Tim-3, Lag-3, etc.) perdent leur activité anti-tumorale. PD-1 est une cible thérapeutique majeure dans le traitement du cancer, mais son expression isolée ne signe pas une dysfonction.
Clémence Granier, Alain Gey, Charles Dariane, Arnaud Mejean, Marc-Olivier Timsit, Charlotte Blanc, Virginie Verkarre, Camélia Radulescu, Elisabeth Fabre, Yann Vano, Stéphane Oudard, Cécile Badoual, Éric Tartour   +12 more
core   +3 more sources

TIM-3 in Cardiovascular Disease. [PDF]

Curr Heart Fail Rep
Abstract Purpose of review We summarise the current knowledge of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) across innate and adaptive immune cells and compile emerging evidence in cardiovascular disease (CVD ...
Yousif LI, Sijtema AG, Chevalier MJ, de Boer RA, Meijers WC.   +4 more
europepmc   +4 more sources

TIM-3 expression in breast cancer [PDF]

OncoImmunology, 2018
Tumor-infiltrating lymphocytes (TILs) are predominantly present in breast cancer patients with estrogen receptor negative tumors, among whom increasing levels correlate with favorable outcomes.
Samantha Burugu, Dongxia Gao, Samuel Leung, Stephen K. Chia, Torsten O. Nielsen   +4 more
doaj   +3 more sources

The role of the TIM-3 receptor in inflammatory bowel disease and autoimmunity: implications for TIM-3 and TCR crosstalk. [PDF]

J Mol Med (Berl)
Abstract The T cell immunoglobulin and mucin-domain receptor 3 (TIM-3) is an immune checkpoint receptor with complex effects on T cell activation and tolerance. TIM-3 is expressed on the surface of T cells in close proximity to the T cell receptor (TCR), where it mainly acts co-inhibitory, despite lacking typical inhibitory ...
Gabel M, Knauss A, Neurath MF, Weigmann B.   +3 more
europepmc   +4 more sources

Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway

Molecular Metabolism, 2019
Objective: Macrophage-mediated inflammation plays a significant role in the development and progression of diabetic nephropathy (DN). However, the underlying mechanisms remain unclear. Studies suggest that T cell immunoglobulin domain and mucin domain-3 (
Chunyang Li, Tixiao Wang, Xiaojia Song   +2 more
exaly   +3 more sources

Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy

OncoImmunology, 2018
Both in vivo data in preclinical cancer models and in vitro data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity.
James Nevin, Xiaomo Jiang, Max Klapholz   +2 more
exaly   +2 more sources

TIM-3, a potential target for sepsis therapy. [PDF]

Chin J Traumatol
Immune dysregulation is one of the leading causes of mortality in patients with sepsis. T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a negative costimulatory molecule, is pivotal for immune regulation during sepsis. The effects of TIM-3 appear to be bidirectional: in the early stages of sepsis, upregulation of TIM-3 may help ...
Huang S, Huang X, Feng X, Wang R, Liao F, Liu D, Sun J, Zhang H, Yu A, Zeng L.   +9 more
europepmc   +3 more sources

Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer [PDF]

Journal of Translational Medicine
Background Colorectal cancer (CRC), the third most common cancer globally, presents challenges like metastasis, recurrence, and therapy resistance.
Gan Tao, Xiuli Guo, Jiaqiang Xiong, Sisi Yan, Xiaowan Guo, Kehua Hu, Wanyi Tai, Lin-lin Bu, Hui Qiu, Qiuji Wu   +9 more
doaj   +2 more sources